metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)
versus Standard of Care (SoC)
	nivolumab alone vs. Standard of Care (SoC)	1	none	inconclusive results for: progression or deaths (PFS); DCR; DOR; objective responses (ORR); AE leading to death (grade 5); STRAE (any grade); TRAE leading to death (grade 5); TRAE leading to discontinuation (any grade); TRAE leading to discontinuation (grade 3-4); Alopecia TRAE (grade 3-4); Arthralgia TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Nausea TRAE (grade 3-4); Peripheral neuropathy TRAE (grade 3-4); Peripheral sensory neuropathy TRAE (grade 3-4); Rash TRAE (grade 3-4); Stomatitis TRAE (grade 3-4)	statistically conclusive 23 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 54 % decrease in STRAE (grade 3-4) but the degree if certainty is unassessable suggested 90 % decrease in TRAE (any grade) but the degree if certainty is unassessable suggested 87 % decrease in TRAE (grade 3-4) but the degree if certainty is unassessable suggested 81 % decrease in Anaemia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 81 % decrease in Decreased appetite TRAE (grade 3-4) but the degree if certainty is unassessable suggested 89 % decrease in Fatigue TRAE (grade 3-4) but the degree if certainty is unassessable suggested 98 % decrease in Febrile neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 99 % decrease in Neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable	-

mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)

versus Standard of Care (SoC)